Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass

Ann Rheum Dis. 2019 Jul;78(7):e71. doi: 10.1136/annrheumdis-2018-213682. Epub 2018 Jun 20.

Authors

Marie Kostine¹, Léa Dousset², Thierry Schaeverbeke¹; FHU-ACRONIM

Affiliations

¹ Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
² Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

PMID: 29925509
DOI: 10.1136/annrheumdis-2018-213682

No abstract available

Keywords: autoimmune diseases; polymyalgia rheumatica; treatment.

Publication types

Letter
Comment

MeSH terms

Azetidines
Giant Cell Arteritis*
Humans
Neoplasms*
Piperidines
Polymyalgia Rheumatica*
Prospective Studies

Substances

Azetidines
Piperidines
cobimetinib